Company intelligence / Profile preview

Gradalis, Inc.

Dallas, Texas, United Statesgradalisinc.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. Phase 2b results have been published in Lancet Oncology and presented at the American Society of Clinical Oncology. The FDA has designated Vigil as a Regenerative Medicine Advanced Therapy (RMAT) for patients with HRP ovarian cancer and high cTMB based on statistically significant and clinically meaningful improvement in overall survival.[2][3][5]

Therapeutic areas: Oncology
Modalities: Personalized immunotherapycellular immunotherapybi-shRNAi technology
Industry: Biotech

Drug pipeline

10 assets

gemogenovatucel-T

9 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Gradalis, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gradalis, Inc..

Explore the full profile